Concurrent Radiotherapy (Due to Radiosensitization) (see Radiation Therapy, [[Radiation Therapy]]): due to risk of mucositis/esophagitis/pneumonitis
Pharmacology
Pyrimidine Analog Which Impairs DNA Synthesis: cell cycle-specific for the S-phase (but also blocks progression at the G1/S-phase)
Gemcitabine is Phosphorylated Intracellularly by Deoxycytidine Kinase to Form Gemcitabine Monophosphate: gemcitabine monophosphate is subsequently phosphorylated to form gemcitabine diphosphate and gemcitabine triphosphate
Gemcitabine Triphosphate Incorporates into DNA and Inhibits DNA Polymerase
Radiation Recall (see Radiation Therapy, [[Radiation Therapy]]): when radiation and gemcitabine are administered >7 days apart
Radiosensitization (see Radiation Therapy, [[Radiation Therapy]]): when radiation and gemcitabine are administered < or equal to 7 days apart
References
Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291
Pulmonary toxicity from treatment with gemcitabine. J Cancer Res Clin Oncol 1998; 124: R163
Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 1998; 11: 504-506
Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study. Cancer Chemother Pharmacol 1998; 41: 217-222
Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1998; 82: 1800-1801
Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998; 114: 1779-1781
Fatal pulmonary toxicity resulting from treatment with gemcitabine and vinorelbine association. Chest 1999; 116: 316
Sudden cardiopulmonary toxicity following a single infusion of gemcitabine. Annals of Oncology 1999; 10: 997
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Annals of Oncology 1999; 10: 943-947 [MEDLINE]
Pulmonary toxicity resulting from treatment with gemcitabine. Onkologie 1999; 22: 146-149
Severe nonhematologic toxicity after treatment with gemcitabine. Proceedings of the American Society of Clinical Oncology 1999; 18: 598a
Non-cardiogenic pulmonary edema during gemcitabine-therapy in 5 patients with bronchial carcinoma. Atemwegs and Lungenkrankheiten 1999; 25: 187
Acute interstitial pneumonitis related to gemcitabine. J Clin Oncol 2000; 18: 697-698
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration 2000; 67: 680-3
Severe acute lung injury induced by gemcitabine. Neth J Med 2000; 56: 232-235
Infrequency of serious pumonary toxicity (SPT) with gemzar (G): analysis of a large database. Proc Am Soc Clin Oncol 2000; 19: 196a
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. European Journal of Cancer 2000; 36: 2329-2334
Gemcitabine-associated diffuse alveolar hemorrhage. Intensive Care Medicine 2001; 27: 1554
Adult respiratory distress syndrome after antineoplastic chemotherapy: probable effect of gemcitabine. Presse Medicale 2001; 30: 851-854
Radiation recall reaction following gemcitabine. Lung Cancer 2001; 33: 299-302
Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. Lung Cancer 2001; 31: 83-85
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003; 98: 978-82
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer; Volume 44, Issue 3, June 2004, Pages 363-368
A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Annals of Oncology 2004; 15: 1250-1255
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer; Volume 44, Issue 3, June 2004, Pages 363-368
Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease. Clinical Oncology 2004; 16: 577-579
Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature. Revue de Medecine Interne 2005; 26: 179-188
Gemcitabine Pulmonary Toxicity in Ovarian Cancer. The Oncologist July 2008 vol. 13 no. 7 807-811
Thrombotic thrombocytopenic purpura and gemcitabine. Case Rep Oncol. 2011 Jan;4(1):143-8. doi: 10.1159/000326801 [MEDLINE]